ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN

Author(s)

Ramirez Boix P1, Cedillo Gomez S2, de Pedro JM1, Jiang Y3, Morell A4, Pascual-Bellosta AM5, Martinez-Ubieto J5
1Merck Sharp & Dohme, Madrid, Spain, 2Chiltern International, Tres Cantos, Spain, 3Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK, 4Hospital Universitario de La Princesa, Madrid, Spain, 5Hospital Universitario Miguel Servet, Zaragoza, Spain

OBJECTIVES

:
Neuromuscular blocking agents (NMBAs) are often administered to prevent patient movement during surgical procedures requiring use of general anesthetics, which can increase the risk of post-operative respiratory complications. Sugammadex is indicated to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults and can efficiently reduce both moderate and deep levels of neuromuscular block. The aim of this study is to estimate clinical and economic impact of sugammadex in routine reversal of neuromuscular blockade with rocuronium in Spain.

METHODS

:
A budget impact model was developed to estimate the aggregated annual net budget impact of substituting sugammadex for neostigmine or no reversal agent in a proportion of patients administered with rocuronium. According to the local data, the annual number of hospital procedures in Spain was 733,876; 73.3% of them would use a NMBA. Rocuronium was administered in 64% of those procedures. Payer perspective was used in the analysis, including only the direct costs associated with post-operative pneumonias and atelectasis and drugs costs. One way sensitivity analysis was carried out by varying each parameter included in the model within a range of +/-50%.

RESULTS

:
The estimated budget impact of the introduction of sugammadex to the routine reversal of neuromuscular blockade in Spanish hospitals was a net saving of €57.1 million annually. A rise in drug acquisition costs was offset by savings in post-operative respiratory events including 4,806 post-operative pneumonias and 13,996 cases of atelectasis. The total cost of complications avoided was €70.4 million. All scenarios tested in sensitivity analysis were favorable to the alternative scenario.

CONCLUSIONS

:
Improving patient safety in the operation room is essential in surgical procedures where neuromuscular blocking agents with rocuronium are required. The clinical benefits in terms of avoided pneumonias and atelectasis with sugammadex would produce net savings for the Spanish National Healthcare System.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PSY52

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Respiratory-Related Disorders, Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×